Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 12/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10256167 | 0.88 | CCND3 (0.49) | MEN1KMT2AJAK2CCNA2CDK2 | |
| SCHEMBL1393372 | 0.85 | NAMPT (0.51) | BTKJAK2JAK1 | |
| SCHEMBL25911767 | 0.84 | BTK (0.47) | MEN1KMT2ABTK | |
| SCHEMBL14926001 | 0.83 | DDB1 (0.52) | MEN1KMT2AJAK2JAK1CCNA2 | |
| SCHEMBL162007 | 0.83 | BTK (0.58) | BTKJAK2 | |
| SCHEMBL10256994 | 0.82 | JAK1 (0.42) | BTKJAK2JAK1 | |
| SCHEMBL1393098 | 0.80 | HDAC1 (0.50) | JAK2JAK1 | |
| SCHEMBL20189098 | 0.80 | BTK (0.58) | BTK | |
| SCHEMBL1392870 | 0.79 | ESR2 (0.52) | JAK2 | |
| SCHEMBL1393097 | 0.79 | MKNK1 (0.33) | BTKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12329821-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20230416242-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4232059-A1 | DOUBLE DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11712458-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3544975-B1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND USE | DANA FARBER CANCER INST INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210100908-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-10925967-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20210030832-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| US-10842878-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3544975-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3544959-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190262458-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190262459-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2018098288-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098275-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416242-A1 | DOUBLE DEGRADERS AND USES THEREOF | DCXR, IDUA, GUSB | MEN1 2854/4885KMT2A 1076/4885ABL1 1091/4885 |
| US-10842878-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | MEN1 3987/4885KMT2A 967/4885ABL1 17/4885 |
| US-11712458-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | MEN1 4259/4885KMT2A 899/4885ABL1 20/4885 |
| US-12329821-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | MEN1 4114/4885KMT2A 1009/4885ABL1 22/4885 |
| US-20210030832-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | MEN1 4259/4885KMT2A 899/4885ABL1 20/4885 |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | MEN1 4114/4885KMT2A 1009/4885ABL1 22/4885 |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | MEN1 4114/4885KMT2A 1009/4885ABL1 22/4885 |
| US-20190262459-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | MEN1 4114/4885KMT2A 1009/4885ABL1 22/4885 |
| US-10925967-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | MEN1 4114/4885KMT2A 1009/4885ABL1 22/4885 |
| US-20210100908-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | MEN1 4114/4885KMT2A 1009/4885ABL1 22/4885 |
| US-20190262458-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | MEN1 3987/4885KMT2A 967/4885ABL1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.